- Home
- HALO vs ELAN Comparison
HALO vs ELAN Comparison
Compare HALO & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- ELAN
- Stock Information
- Founded
- HALO 1998
- ELAN 1954
- Country
- HALO United States
- ELAN United States
- Employees
- HALO N/A
- ELAN N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- HALO Health Care
- ELAN Health Care
- Exchange
- HALO Nasdaq
- ELAN Nasdaq
- Market Cap
- HALO 6.4B
- ELAN 6.3B
- IPO Year
- HALO N/A
- ELAN 2018
- Fundamental
- Price
- HALO $50.51
- ELAN $11.92
- Analyst Decision
- HALO Buy
- ELAN Buy
- Analyst Count
- HALO 9
- ELAN 7
- Target Price
- HALO $61.11
- ELAN $16.71
- AVG Volume (30 Days)
- HALO 1.3M
- ELAN 4.0M
- Earning Date
- HALO 02-18-2025
- ELAN 02-24-2025
- Dividend Yield
- HALO N/A
- ELAN N/A
- EPS Growth
- HALO 61.71
- ELAN N/A
- EPS
- HALO 3.02
- ELAN 0.41
- Revenue
- HALO $947,355,000.00
- ELAN $4,454,000,000.00
- Revenue This Year
- HALO $23.36
- ELAN $2.24
- Revenue Next Year
- HALO $15.35
- ELAN $2.79
- P/E Ratio
- HALO $16.69
- ELAN $28.79
- Revenue Growth
- HALO 21.35
- ELAN 1.99
- 52 Week Low
- HALO $33.15
- ELAN $11.40
- 52 Week High
- HALO $65.53
- ELAN $18.80
- Technical
- Relative Strength Index (RSI)
- HALO 59.63
- ELAN 42.03
- Support Level
- HALO $47.52
- ELAN $11.64
- Resistance Level
- HALO $49.00
- ELAN $12.41
- Average True Range (ATR)
- HALO 1.39
- ELAN 0.40
- MACD
- HALO 0.38
- ELAN 0.04
- Stochastic Oscillator
- HALO 93.30
- ELAN 43.30
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.